Sana Biotechnology Shares Climb on Positive Diabetes Study Results

Dow Jones

Jun 23, 2025

By Dean Seal

Shares of Sana Biotechnology jumped after the company reported positive results for the latest study transplanting its UP421 cell therapy into a patient with type 1 diabetes.

The stock was up 21% at $3.16 in early trading. Shares were changing hands at $5.51 a year ago but are up 94% so far in 2025.

The Seattle company said a six-month follow-up with the patient showed the transplanted allogeneic primary islet cell engineered with Sana's hypoimmune technology were safe and well-tolerated.

An MRI scanning showed signals that were consistent with graft survival six months after transplantation, Sana said.

"The data presented today bring our vision--treating diabetes with a broadly available therapy leading to normal blood glucose control without either insulin or immunosuppression--closer to reality," Chief Executive Steve Harr said.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

June 23, 2025 10:33 ET (14:33 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2545448138"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545448138\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2545448138?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-23 22:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545448138","market":"nz","top_or_hot":-1,"title":"Sana Biotechnology Shares Climb on Positive Diabetes Study Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Dean Seal \n</p>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/SANA\">Sana Biotechnology</a> jumped after the company reported positive results for the latest study transplanting its UP421 cell therapy into a patient with type 1 diabetes. \n</p>\n<p>\n  The stock was up 21% at $3.16 in early trading. Shares were changing hands at $5.51 a year ago but are up 94% so far in 2025. \n</p>\n<p>\n  The Seattle company said a six-month follow-up with the patient showed the transplanted allogeneic primary islet cell engineered with Sana's hypoimmune technology were safe and well-tolerated. \n</p>\n<p>\n  An MRI scanning showed signals that were consistent with graft survival six months after transplantation, Sana said. \n</p>\n<p>\n  \"The data presented today bring our vision--treating diabetes with a broadly available therapy leading to normal blood glucose control without either insulin or immunosuppression--closer to reality,\" Chief Executive Steve Harr said. \n</p>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 23, 2025 10:33 ET (14:33 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sana Biotechnology Shares Climb on Positive Diabetes Study Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSana Biotechnology Shares Climb on Positive Diabetes Study Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-06-23 22:33</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Dean Seal \n</p>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/SANA\">Sana Biotechnology</a> jumped after the company reported positive results for the latest study transplanting its UP421 cell therapy into a patient with type 1 diabetes. \n</p>\n<p>\n  The stock was up 21% at $3.16 in early trading. Shares were changing hands at $5.51 a year ago but are up 94% so far in 2025. \n</p>\n<p>\n  The Seattle company said a six-month follow-up with the patient showed the transplanted allogeneic primary islet cell engineered with Sana's hypoimmune technology were safe and well-tolerated. \n</p>\n<p>\n  An MRI scanning showed signals that were consistent with graft survival six months after transplantation, Sana said. \n</p>\n<p>\n  \"The data presented today bring our vision--treating diabetes with a broadly available therapy leading to normal blood glucose control without either insulin or immunosuppression--closer to reality,\" Chief Executive Steve Harr said. \n</p>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 23, 2025 10:33 ET (14:33 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SANA","symbol_name":"Sana Biotechnology, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2545448138","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545448138","pubTimestamp":1750689180,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Sana Biotechnology jumped after the company reported positive results for the latest study transplanting its UP421 cell therapy into a patient with type 1 diabetes.The stock was up 21% at $3.16 in early trading. Shares were changing hands at $5.51 a year ago but are up 94% so far in 2025.The Seattle company said a six-month follow-up with the patient showed the transplanted allogeneic primary islet cell engineered with Sana's hypoimmune technology were safe and well-tolerated.An MRI scanning showed signals that were consistent with graft survival six months after transplantation, Sana said.\"The data presented today bring our vision--treating diabetes with a broadly available therapy leading to normal blood glucose control without either insulin or immunosuppression--closer to reality,\" Chief Executive Steve Harr said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SANA":"Sana Biotechnology, Inc.","BK4139":"生物科技"},"translate_title":"Sana Biotechnology股价因糖尿病研究结果积极而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SANA":1},"content_text":"By Dean Seal \n\n\n  Shares of Sana Biotechnology jumped after the company reported positive results for the latest study transplanting its UP421 cell therapy into a patient with type 1 diabetes. \n\n\n  The stock was up 21% at $3.16 in early trading. Shares were changing hands at $5.51 a year ago but are up 94% so far in 2025. \n\n\n  The Seattle company said a six-month follow-up with the patient showed the transplanted allogeneic primary islet cell engineered with Sana's hypoimmune technology were safe and well-tolerated. \n\n\n  An MRI scanning showed signals that were consistent with graft survival six months after transplantation, Sana said. \n\n\n  \"The data presented today bring our vision--treating diabetes with a broadly available therapy leading to normal blood glucose control without either insulin or immunosuppression--closer to reality,\" Chief Executive Steve Harr said. \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 23, 2025 10:33 ET (14:33 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}